New Medicine's Oncology Knowledgebase is a dynamic, daily updated, fully relational, user-friendly, comprehensive resource in global drug development in oncology Why use a resource like nm/OK? Unlike reports that are 'dead on arrival' nm/OK is a constantly updated comprehensive report on every aspect of oncology drug development. Drugs profiled in nm/OK - nm/OK profiles over 4,139 drugs/in vivo imaging agents in development: - 3,296 anticancer agents addressing over 100 cancer types and thousands of clinical indications. Of these, 1,695 are in active development; 821 are in clinical trials and 528 of these are targeted agents. - 757 drugs for the management of complications of cancer and its treatment (pain, infection, mucositis, emesis, etc.) - nm/OK also profiles over 552 marketed drugs (anticancer agents=335, adjuncts=197) globally, providing trial results from monotherapy and combination therapy trials. In vitro testing (IVT) products nm/OK profiles over 200 companies and hundreds of products (screening tests, diagnostics, pharmacogenomics, prognostics, disease monitoring tests, theragnostics, etc.) in the in vitro testing area in oncology. Enabling technologies/drug delivery nm/OK describes hundreds of technology platforms used to discover, evaluate, optimize, and or deliver anticancer agents such as cytotoxics, synthetic nucleic acid sequences, small molecule drugs, monoclonal antibodies, fusion proteins, etc. Targets in oncology nm/OK describes over 1,000 molecular moieties that may be target candidates of anticancer strategies or used as in vitro testing markers.